I personally think it is dead in the water. If it happens it would be a plus but I'm expecting it or factoring it in to my "investment" plan in Z. The plus would be more in validating the cHTS platform that in the short term impact on the pps. Long term it would change some of the negative constructs people have on the platform.
Slug, regarding the cHTS validating factor it's enough the Novartis contract renewal IMHO.
Something will come out of the pot soon or later and considering actual pps and Novartis target it would be huge for ZLCS.
FOV1101 is not dead but just delayed for the reasons we know.
As soon as it enters Ph.III Zlcs will clearly rebound ( if not happened already)